Big Pharma names sit on UK panel shaping fallout from US-UK drugs trade pact

Nine of the world's largest pharmaceutical companies have been seated alongside UK government officials on a new oversight committee charged with implementing the US-UK pharmaceuticals trade agreement, in a sign of how heavily the Trump administration's drug pricing reset is reshaping the commercial environment for medicines on both sides of the Atlantic.

AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Eli Lilly, Pfizer, Roche, Sanofi and UCB all sit on the US-UK Pharmaceuticals Agreement Oversight Committee, according to a Department of Health and Social Care response to a freedom of information request. The two principal industry bodies, the Association of the British Pharmaceutical Industry and the BioIndustry Association, are also represented, alongside NHS England — the budget holder for specialised medicines — and the National Institute for Health and Care Excellence, the UK's health technology assessment agency.

The line-up has been criticised on the grounds that it excludes generic manufacturers, despite the fact that the bilateral agreement reshapes the future of VPAG, the UK's voluntary pricing scheme, which covers branded generic products as well as new branded medicines. All nine companies are members of the ABPI and were selected by the government, according to an industry source. The committee is distinct from the Pharmaceutical Supply Chains Partnership referred to in the more detailed text of the US-UK agreement published on 2 April.

The deal, agreed against a backdrop of intense pressure from Washington over global drug pricing, commits the UK to a series of measures designed to lift returns for innovative medicines. The headline cost-effectiveness threshold used by NICE will rise from its long-standing baseline to a range of £25,000 to £35,000 per quality-adjusted life year, with a new weighting applied to quality-of-life calculations. VPAG rebates on new medicines will be capped at 15 per cent — a structural shift away from the variable, expenditure-driven rate that has historically characterised the scheme — and the agreement explicitly prevents the headline increase in NHS spending on innovative medicines from being clawed back through deeper discounts or higher rebates elsewhere.

Government spending commitments are similarly aggressive. Outlays on new medicines are to rise to 0.35 per cent of GDP by the end of 2028, 0.4 per cent by the end of 2030 and 0.6 per cent by the end of 2036, by which point the share of total NHS health expenditure devoted to medicines is targeted to rise from 10 per cent to 12 per cent.

The committee's immediate focus is a rapid review of the UK operating environment, with four sequential "sprints" planned between now and June. Discussions are expected to range across UK competitiveness, economic growth, and ideas for improving pricing, access and uptake — with the most promising proposals potentially piloted, including new pricing models. The committee will also examine the practical levers the government can pull to deliver on its spending commitments.

Already in train is the negotiation of a successor to VPAG, which expires on 31 December 2028. Reports suggest the Trump administration is pushing for an accelerated timetable on the next scheme, and the committee is expected to play a central role in shaping it. The ABPI has indicated that the next iteration will also draw input from charitable patient groups in addition to industry, NHS England and NICE.

A second meeting of the committee is scheduled for 28 April, following an initial gathering on 5 March, according to the FOI disclosure.

The composition of the panel underlines how the architecture of UK medicines pricing is being reshaped under bilateral pressure from Washington — and how the major branded drugmakers, long frustrated by the constraints of the British system, have secured a direct seat at the table as the rules are rewritten.